Heredity and the autonomic nervous system in human hypertension

Current Hypertension Reports

Volumn 2, Issue 1, 2000, Pages 16-22

  O'Connor, Daniel T ^a   Insel, Paul A ^a   Ziegler, Michael G ^a   Hook, Vivian Y ^a   Smith, Douglas W ^a   Hamilton, Bruce A ^a   Taylor, Palmer W ^a   Parmer, Robert J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; CHROMOGRANIN;

AUTONOMIC NERVOUS SYSTEM; BLOOD; CHROMOSOME 5; GENETICS; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; REVIEW;

AUTONOMIC NERVOUS SYSTEM; CHROMOGRANINS; CHROMOSOMES, HUMAN, PAIR 5; HUMANS; HYPERTENSION; PHENOTYPE; RECEPTORS, ADRENERGIC;

EID: 0034135982     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-000-0053-8     Document Type: Article

References (77)

1. Izzo JL, Black HR: Hypertension Primer. Dallas, Texas: American Heart Association; 1993.
2. Lifton RP: Molecular genetics of human blood pressure variation. Science 1996, 272: 676-80.
3. Lander E, Schork N: Genetic dissection of complex traits. Science 1994, 265: 2037-48.
4. Hunt SC, Williams RR: Genetic factors, family history, and blood pressure. In Hypertension Primer. Edited by Izzo JL, Black HR. Dallas, Texas: American Heart Association; 1993: 155-158.
5. Hunt SC, Williams RR: Genetic factors in human hypertension. In Textbook of Hypertension. Edited by Swales JD. Oxford: Blackwell Scientific; 1994: 519-538.
6. Ward R: Familial aggregation and genetic epidemiology of blood pressure. In Hypertension: Pathophysiology, Diagnosis, and Management, vol 1. Ed by Laragh JH, Brenner BM. New York: Raven Press; 1990: 81-100.
7. Jacob HJ, Lindpaintner L, Lincoln SE, et al.: Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. Cell 1991, 67: 213-224.
8. Hilbert P, Lindpaintner K, Beckmann JS, et al.: Chromosomal mapping of two genetic loci associated with blood-pressur regulation in hereditary hypertensive rats. Nature 1991, 353, 521-529.
9. Wright FA, O'Connor DT, Roberts E, et al.: Genome scan for blood pressure loci in mice. Hypertension 1999, 34: 625-630.
10. Falconer DS, Mackay TFC: Heritability. In Introduction to Quantitative Genetics, edn 4. Harlow, England: Longman; 1996: 160-183.
11. Cavalli-Sforza LL, Bodmer WF: Quantitative characters, polygenic inheritance, and environmental interactions. In The Genetics of Human Populations. San Francisco: WH Freeman and Co.; 1971: 508-633.
12. Miall WE, Oldham PD: The hereditary factor in arterial blood pressure. BMJ 1963, 19: 75-80.
13. Khoury MJ, Beaty TH, Cohen BH: Genetic approaches to familial aggregation II. Segregation analysis. In Fundamentals of Genetic Epidemiology. Edited by Khoury MJ, Beaty TH, Cohen BH. New York: Oxford University Press; 1993: 233-283.
14. Weissbecker KA: Segregation analysis of diastolic blood pressure in a large pedigree. Genet Epidemiol 1993, 10: 659-664.
15. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al.: Molecular basis of human hypertension: role of angiotensinogen. Cell 1992, 71: 7-20.
16. O'Donnell CJ, Lindpaintner K, Larson MG, et al.: Evidence for association and genetic linkage of the angiotensin convert ing enzyme locus with hypertension and blood pressur in men but not women in the Framingham Heart Study. Circulation 1998, 97: 1766-1772.
17. Fornage M, Amos CI, Kardia S, et al.: Variation in the region of the angiotensin converting enzyme gene influences interindividual differences in blood pressure levels in young white males. Circulation 1998, 97: 1773-1779.
18. 2), ADRA1B (alpha1B), and DRD1 (dopamineD1)].
19. Kailasam MT, Diggle K, Wilson AF, et al.: Linkage of alpha adrenergic pressor responsiveness to chromosome 5q in hypertensive families [abstract]. Hypertension 1998, 32: 593. Sib-pair quantitative trait linkage established a role for allelic variation in the chromosome 5q region in the response to infused pressor agents in families ascertained by a proband with essential hypertension. The 5q region includes such adrenergic receptor candidate genes as ADRB2(beta2), ADRA1B (alpha1B), and DRD1 (dopamineD1).
20. Williams RR, Hunt SC, Hasstedt SJ, et al.: Are there interactions and relations between genetic and environ mental factors predisposing to high blood pressure? Hypertension 1991, 18(suppl 3):129-137.
21. Williams RR, Hunt SC, Hasstedt SJ, et al.: Multigenic human hypertension: evidence for subtypes and hope for haplotypes. J Hypertens 1990, 8(suppl 7):39-46.
22. Bianchetti MG, Beretta-Piccoli C, Weidmann P, Ferrier C: Blood pressure control in normotensive members o hypertensive families. Kidney Int 1986, 29: 882-888.
23. Dao TT, Kailasam MT, Parmer RJ, et al.: Expression of altered alpha2 adrenergic phenotypic traits in normo tensive humans at genetic risk of hereditary (essential) hypertension. J Hypertens 1998, 16: 779-792. Detection of alterations in a-2-adrenergic responses in a subset of still-normotensive individuals at genetic risk of hypertension, by virtue of positive family history. The use of maximum likelihood analysis to establish bimodality is illustrated.
24. Takiyyuddin MA, Parmer RJ, Kailasam MT, et al.: Chromogranin A in human hypertension: influence of heredity. Hypertension 1995, 26: 213-220. The use of human twins (monozygotic and dizygotic) to explore the heritability of a biochemical autonomic trait in hypertension.
25. Parmer RJ, Cervenka JH, Stone RA: Baroreflex sensitivity and heredity in essential hypertension. Circulation 1992, 85: 497-503. Diminished baroreceptor function in human essential hypertension has been observed for many years. This report established that even the still-normotensive offspring of essential hypertensive patients already display diminished baroreflex slope, suggesting a pathogenic role for this autonomic trait in the later development of hypertension.
26. Williams GH, Dluhy RG, Lifton RP, et al.: Nonmodulation as an intermediate phenotype in essential hypertension. Hypertension 1992, 20: 788-796.
27. Miller LM, Tyrell EA, Kailasam MT, et al.: Early alteration in glomerular response to amino acids in humans at genetic risk of essential hypertension [abstract]. Hypertension 1998, 32: 602.
28. Brinton TJ, Kailasam MT, Wu RA, et al.: Arterial compliance by cuff sphygmomanometer: application to hypertension and early changes in subjects at genetic risk. Hypertension 1996, 28: 599-603.
29. Grunfeld B, Balzareti M, Romo M, et al.: Hyperinsulinemia in normotensive offspring of hypertensive parents. Hyp ertension 1994, 23(suppl 1):12-15.
30. Kailasam MT, Fineman MS, Koda JE, et al.: Circulating amylin in human essential hypertension: racial differences and early elevations in subjects at genetic risk of hypertension [abstract]. J Invest Med 1995, 43(suppl 2):266.
31. Lacy F, O'Connor DT, Schmid-Schonbein GW: Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens 1998, 16: 291-303.
32. Kailasam MT, O'Connor DT, Parmer RJ: Hereditary intermediate phenotypes in African-American hypertension. Ethn Health 1996, 1: 133-144.
33. Terwilliger JD, Ott J: Handbook of Human Genetic Linkage. Baltimore: Johns Hopkins University Press; 1994: 307.
34. Buescher R, Herrmann V, Insel PA: Human adrenoceptor polymorphisms: evolving recognition of clinical importance. Trends Pharmacol Sci 1999, 20: 94-99. Comprehensive review of reported variations in the genes for human adrenergic receptors and their associations with common human diseases.
35. Buescher R, Hermann V, Ring KM, et al.: Variability in phenylephrine response and essential hypertension: a search for human alpha-1B-adrenergic receptor polymorphisms. J Pharmacol Exper Therap 1999, 291: 793-798. An attempt to find polymorphisms by resequencing an adrenergic candidate gene (ADRA1B on chromosome 5q) for human hypertension.
36. Goldstein DS, Kopin IJ: The autonomic nervous system and catecholamines in normal blood pressure control and in hypertension. In Hypertension: Pathophysiology, Diagnosis and Management. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1990: Page Range.
37. Mancia G, Grassi G, Giannattsio C, Seravalle G: Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999, 34: 724-728.
38. Bolli P, Kiowski W, Buhler FR: The pathophysiology of the sympathetic nervous system in human hypertension. Studies using specific pharmacologic probes. In Hypertension: Pathophysiology, Diagnosis, and Management, edn 2. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995: 923-940.
39. Bachmann AW, Ballantine DM, Gordon RD: Effect of positive family history of hypertension on the blood pressure and catecholamine responses to a 6 hour adrenaline infusion. Clin Exp Pharmacol Physiol 1993, 20: 395-398.
40. De Lima JJ, Dias MM, Bernardes-Silva H, Bellotti G: Pressor response to norepinephrine in essential hypertension: a study in families. Hypertension 1990, 15(suppl 2):137-139.
41. Falkner B, Onesti G, Angelakos ET, et al.: Cardiovascular response to mental stress in normal adolescents with hypertensive parents: hemodynamics and mental stress in adolescents. Hypertension 1979, 1: 23-30.
42. Ferrier C, Cox H, Esler M: Elevated total norepinephrine spillover in normotensive members of hypertensive families. Clin Sci 1993, 84: 225-230.
43. Takiyyuddin MA, Cervenka JH, Hsiao RJ, et al.: Chromogranin A: storage and release in hypertension. Hypertension 1990, 15: 237-246.
44. Takiyyuddin MA, Cervenka JH, Sullivan PA, et al.: Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation 1990, 81: 185-195.
45. Eskeland NL, Zhou A, Dinh TQ, et al.: Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases. J Clin Invest 1996, 98: 148-156.
46. Tatemoto K, Efendic S, Mutt V, et al.: Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 1986, 324: 476-478.
47. Aardal S, Helle KB: The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept 1992, 41: 9-18.
48. Helle KB, Marley PD, Hogue-Angeletti R, et al.: Chromogranin A: secretion of processed products from the stimulated retrogradely perfused bovine adrenal gland. J. Neuroendocrinol 1993, 5: 413-420.
49. Mahata SK, O'Connor DT, Mahata M, et al.: Novel autocrine feedback control of catecholamine release: a discrete chromogranin A fragment is a non-competitive nictotinic cholinergic antagonist. J Clin Invest 1997, 100: 1623-1633. Chromogranin A344-364 ("catestatin") is a potent inhibitor of catecholamine release, acting as a nicotinic cholinergic antagonist. Because catestatin is coreleased with catecholamines by exocytosis, the peptide may participate in a novel negative-feedback or "brake" pathway on catecholamine release.
50. Dimsdale JE, O'Connor DT, Ziegler M, Mills P: Chromogranin A correlates with norepinephrine release rate. Life Sci 1992, 51: 519-525.
51. O'Connor DT, Takiyyuddin MA, Printz MP, et al.: Catecholamine storage vesicle protein expression in genetic hypertension. Blood Pressure 1999, in press.
52. Mahata SK, Kozak CA, Szpirer J, et al.: Dispersion of chromogranin/secretogranin secretory protein family loci in mammalian genomes Genomics 1996, 33: 135-139.
53. Simon-Chazottes D, Wu H, Parmer RJ, et al.: Assignment of the chromogranin A (Chga) locus to homologous regions on mouse chromosome 12 and rat chromosome 6. Genomics 1993, 17: 252-255.
54. Parmer RJ, Cervenka JH, Stone RA, O'Connor DT: Autonomic function in hypertension: are there racial differences? Circulation 1990, 81: 1305-1311.
55. Nowak SJ: Chronic hypertension produced by carotid sinus and aortic nerve section. Ann Surg 1940, 111: 102-111.
56. Green MF, DeGroat AF, McDonald CH: Observations on denervation of the carotid sinuses and section of the depressor nerves as a method of producing arterial hypertension. Am J Physiol 1935, 110: 513-520.
57. Carey RM, Dacey RG, Jane JA, et al.: Production of sustained hypertension by lesions in the nucleus tractus solitarius of the American foxhound. Hypertension 1979, 1: 246-254.
58. Wu RA, Kailasam MT, Cervenka JH, et al.: Does lipophilicity of angiotensin converting enzyme inhibitors selectively influence autonomic neural function in human hypertension? J Hypertens 1994, 12: 1243-1247.
59. Cohen IM, O'Connor DT, Preston RA, Stone RA: Long-term clonidine effects upon autonomic function in essential hypertensive man. Eur J Clin Pharmacol 1981, 19: 25-32.
60. Sasso EH, O'Connor DT: Prazosin depression of baroreflex function in hypertensive man. Eur J Clin Pharmacol 1982, 22: 7-14.
61. O'Connor DT, Preston RA: Propranolol effects upon autonomic function in hypertensive man. Clin Cardiol 1982, 5: 340-346.
62. Brodde OE, Stuka N, Demuth V, et al.: Alpha- and beta-adrenoceptors in circulating blood cells of essential hypertensive patients: increased receptor density and responsiveness. Clin Exp Hypertens 1985, 7: 1135-1150.
63. Fritschka E, Kribben A, Haller H, et al.: Familial aggregation of altered adrenoceptor density and free intracellular calcium in patients with essential hypertension. J Cardiovasc Pharmacol 1987, 10(suppl 4):122-125.
64. Umemura S, Uchino K, Yasuda G, et al.: Altered platelet alpha2-adrenoceptors and adrenaline response in adolescents with borderline hypertension who have a family history of essential hypertension. J Hypertens 1988, 6(suppl 4):568-571.
65. Michel MC, Galal O, Stoermer J, et al.: Alpha- and beta-adrenoceptors in hypertension. II. Platelet alpha2- and lymphocyte beta2-adrenoceptors in children of patients with essential hypertension. J Cardiovasc Pharmacol 1989, 13: 432-439.
66. Umemura S, Hirawa N, Hayashi S, et al.: Effect of dietary sodium on platelet alpha 2-adrenoceptors in young normotensive men with or without a family history of hypertension. J Hypertens 1992, 10: 1397-1401.
67. Motulsky HJ, O'Connor DT, Insel P: Platelet alpha adrenergic receptors are normal in untreated and treated hypertensive man. Clin Sci Mol Med 1983, 64: 265-272.
68. Propping P, Friedle W: Genetic control of adrenergic receptors on human platelets: a twin study. Hum Genet 1983, 64: 105-109.
69. Goldberg MR, Hollister AS, Robertson D: Influence of yohimbine on blood pressure, autonomic reflexes, and plasma catecholamines in humans. Hypertension 1983, 5: 772-778.
70. Goldberg MR, Robertson D: Yohimbine: a pharmacological probe for study of the alpha2-adrenoceptor. Pharmacol Revi 1983, 35(2):143-180.
71. Goldstein DS, Grossman E, Listwak S, Folio CJ: Sympathetic reactivity during a yohimbine challenge test in essential hypertension. Hypertension 1991, 18(suppl 5):40-48.
72. Lockette W, Ghosh S, Farrow S, et al.: Alpha2-adrenergic receptor gene polymorphism and hypertension in blacks. Am J Hypertens 1995, 8: 390-394.
73. Sun L, Schulte N, Pettinger P, et al.: The frequency of alpha 2-adrenoceptor restriction fragment length polymorphisms in normotensive and hypertensive humans. J Hypertens 1992, 10: 1011-1015.
74. Umemura S, Hirawa N, Iwamoto T, et al.: Association analysis of restriction fragment length polymorphism for alpha2-adrenergic receptor genes in essential hypertension in Japan. Hypertension 1994, 23(suppl 1):203-206.
75. Insel PA: GTP-binding proteins and post-receptor components in hypertension. Pharmacol Toxicol 1992, 70: 28-31.
76. Siffert W, Rosskopf D, Siffert G, et al.: Association of a human G-protein beta3 subunit variant with hypertension. Nature Genet 1998, 18: 45-48.
77. Jia H, Hingorani AD, Sharma P, et al.: Association of the G (s) alpha gene with essential hypertension and response to beta-blockade. Hypertension 1999, 34: 8-14.